The last 7 days have been challenging for the blood thinner market.
Last week, the FDA put the breaks on J&J’s Xarelto and gave them an approvable on their risk prevention claims. Now this week brings bad news for Pfizer and BMS’ Eliquis (apixaban).
Today, the FDA gave Pfizer and Bristol-Myers Squibb a complete response letter on their blood thinner Eliquis. Good news is that the FDA is not looking for new trials, only clarifications on existing trials and data. But it is still going to be a costly delay for both companies, which are already smarting from major patent expirations.